Health Canada has authorized the updated COVID-19 vaccine from Pfizer-BioNTech this week, making it the third vaccine formulation to receive approval this month.
The mRNA vaccine developed by Pfizer-BioNTech is designed to target the KP.2 subvariant of Omicron. Known as Comirnaty, the new vaccine replaces the prior shot that was meant to protect against the XBB.1.5 Omicron subvariant, the company said in a press release.
